CVR - Coronavirus Vaccines R&D Roadmap

Milestone
3.2.c

Expanded breadth

Completed
Ongoing

Encourage, promote, and publicize collaborations among researchers and developers aimed at expanding breadth of coronavirus vaccine coverage, such as assessing combinations of vaccines or different antigens in animal models or early clinical trials, or assessing prime-boost combinations of different approved or candidate vaccines.

Progress Highlights

As of April 2024, the CEPI Centralized Laboratory Network (CLN) has expanded to 17 laboratories from 13 different countries, with 5 of those countries being classified as low income or lower middle income; this expansion streamlines and harmonizes the assessment of vaccine candidates against emerging infectious diseases.

NIAID CIVICs conducts research on SARS-CoV-2 in addition to influenza, and has 71 studies containing the keyword “coronavirus” in the CIVICs Publications database with publication dates 2023–2025.